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Abstract
Background: The aim of this study was evaluate the late-onset repercussions of heart alterations of patients with
systemic lupus erythematosus (SLE) after a 13-year follow up.
Methods: A historical prospective study was carried out involving the analysis of data from the charts of patients
with a confirmed diagnosis of lupus in follow up since 1998. The 13-year evolution was systematically reviewed and
tabulated to facilitate the interpretation of the data.
Results: Forty-eight patient charts were analyzed. Mean patient age was 34.5 ± 10.8 years at the time of diagnosis
and 41.0 ± 10.3 years at the time of the study (45 women and 3 men). Eight deaths occurred in the follow-up
period (two due to heart problems). Among the alterations found on the complementary exams, 46.2% of cases
demonstrated worsening at reevaluation and four patients required a heart catheterization. In these cases, coronary
angioplasty was performed due to the severity of the obstructions and one case required a further catheterization,
culminating in the need for surgical myocardial revascularization.
Conclusion: The analysis demonstrated progressive heart impairment, with high rates of alterations on
conventional complementary exams, including the need for angioplasty or revascularization surgery in four patients.
These findings indicate the need for rigorous cardiac follow up in patients with systemic lupus erythematosus.
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Background
Systemic lupus erythematosus (SLE) is an inflammatory
autoimmune syndrome of unknown cause that affects
multiple organs, with a broad spectrum of manifestations
and a clinical status marked by periods of exacerbation
and remission, with a variable course and prognosis. This
immunoregulatory disorder is suggested to be related with
genetic, hormonal and environmental factors, resulting in
chronic inflammation [1]. Antibodies act against a variety
of structures, including double-helix DNA, cytoplasm
antigens and antigens on the surface of cells [2]. Tissue
damage may occur through the formation of immune
complexes in the circulation or the presence of such sites
in antigens attached to the tissues [3], involving different
organs, such as the lungs, heart, kidneys, brain, peripheral
nerves, skin, serous membrane and blood components.
SLE occurs throughout the world, with prevalence rates
ranging from 15 to 50/100,000 inhabitants. This disease
predominantly affects the female gender (9:1) and the first
symptoms commonly emerge between the second and
third decades of life [4].
Although rare as an initial manifestation of the disease,
the heart is affected in more than 50% of cases, with sig-
nificant illness and mortality rates, pericarditis, myocar-
ditis, Libman-Sacks endocarditis, pulmonary arterial
hypertension and coronary disease are considered the
main cardiovascular conditions associated with auto-
immune alterations in SLE. In 1895, William Osler was
the first to consider heart damage as part of this disease.
Libman & Sacks [5] brought the world’s attention to a
form of heart impairment the authors considered to be
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specific to Lupus, describing post-mortem findings of a
form of non-infectious endocarditis, denominated typical
verrucous endocarditis, in four patients with clinical data
suggestive of SLE.
The frequency of heart complications in SLE is quite
variable and depends on the population studied, follow-
up period and methods employed in the diagnosis. Peri-
carditis and/or pericardial effusion are reported in 11 to
58% of cases, heart valve disease is reported in 6 to 84%,
myocarditis is reported in 5 to 75%, systemic arterial
hypertension is reported in 22 to 69%, heart failure is
reported in 7 to 44%, ischemic coronary disease is
reported in 5 to 16% and pulmonary hypertension is
reported in 9 to 43% of cases [6-13].
In view of the above considerations, the objective of
the study is to evaluate the evolution of patients with
systemic lupus erythematosus after a 13-year follow up
to analyze late-onset repercussions of heart alterations
and determine the prognostic value of such an analysis.
Method
A historical prospective study was carried out involving
the analysis of data from the charts of patients with a
confirmed diagnosis of SLE based on the criteria of the
American College of Rheumatology treated at the
Rheumatology Sector of the São Jose do Rio Preto
School of Medicine (state of São Paulo, Brazil) between
January 1996 and May 1997. The subjects were included
in the master’s degree dissertation of one of the authors
(GRLB) [7] and reevaluated in a historical prospective
fashion with the aim of following the long term
evolution of SLE in relation to cardiac complications.
The study was approved by the Ethical committee in
Research of the University in which the study was
performed (Number 156/2009).
All cardiovascular exams performed since May 2009
were analyzed again for the detection of heart complica-
tions. The occurrence of cardiovascular events (angina/
infarction, stroke, heart failure, arrhythmia and cardiac
death) was evaluated, along with the determination of
the Kaplan-Meier survival curve. For the purposes of
systematization, the data was considered in three-year
periods (1998 to 2000; 2001 to 2003; 2004 to 2006; and
2007 to 2009).
To analyses the late-onset repercussions, the following
exams on the patients charts were used: chest x-ray,
electrocardiogram, echocardiogram, cardiac stress test
and coronary angiography. The need for invasive proce-
dures for myocardial revascularization (angioplasty or
surgery) was also evaluated.
All patients were followed, however, not everyone did
all exams. The 26 patients that performed X-ray are not
exactly the same 24 that performed ECG, which also
cannot match the 10 tested for effort tests. The tests
were made along the clinical follow-up, which was
appointed in accordance with the need and best judg-
ment of the clinician professionals.
Results
Forty-eight charts of patients with a confirmed diagnosis
of SLE and followed up since 1998 were analyzed, 45
(93.7%) of which belonged to female patients. Mean age
was 34.5 ± 10.8 at the time of diagnosis and 41.7 ± 10.3
at the time of the analysis. Ethnic background was pre-
dominantly Caucasian (32 individuals; 66.6%), followed
by Mulatto (10 individuals) and African-descent (6 indi-
viduals). Mean follow up was 7.2 ± 5.1 years (maximum:
13.6 years). Arterial hypertension was found in 30
patients (62.5%); myocardial infarction occurred in four
patients (8.33%), cerebrovascular accident (stroke) was
found in three patients (4.1%); and pulmonary thrombo-
embolism occurred in one patient (2%).
Chest x-ray
In the sequential evaluation of the four three-year
periods, 26 patients were reevaluated, six of whom
exhibited significant alterations: five had a normal x-ray
and presented worsening and one had an altered x-ray
with a worsening throughout the follow up. Seven pa-
tients had alterations on the x-ray with no worsening of
the condition. Thirteen patients had normal x-rays and
remained without changes throughout the follow up.
Evaluation was not possible for 22 patients due to losses
occurring in the last 10 years of follow up; 13 of these
patients had no initial alterations and nine had initial
alterations. The alterations in these patients were an
increased cardiothoracic ratio, with no signs of pulmon-
ary venocapillary hypertension.
Electrocardiogram
In the sequential evaluation of the four three-year
periods, 24 patients were reevaluated, ten of whom
exhibited significant alterations: eight had a normal elec-
trocardiogram and suffered complications and two had
an altered electrocardiogram with an exacerbation of the
complication throughout the follow up. Three patients
had alterations with no worsening of the condition. Eleven
patients had a normal electrocardiogram and remained
without alterations throughout the follow up. Evaluation
was not possible for 24 patients due to losses occurring in
the last 10 years of follow up; 11 of these patients had
initial alterations and 13 had no initial alterations. All
patients exhibited sinus rhythm throughout the study.
Left ventricular (LV) overload was found in one pa-
tient in the third three-year period and two patients in
the fourth three-year period. Left atrial overload was
found in one patient in the fourth three-year period.
Myocardial ischemia was found in one patient in the
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first three-year period, one in the second three-year
period and two in the third three-year period; the sites
of the ischemia were the inferior-apical-lateral, inferior
and anteroseptal epicardium. Necrosis was found in one
patient in the first three-year period, one in the second
three-year period and two in the third three-year period.
Altered repolarization was found in two patients in the
first three-year period, five in the second three-year
period, two in the third three-year period and one in the
fourth three-year period. Heart arrhythmia (character-
ized by ventricular extrasystoles) was found in one pa-
tient in the first three-year period and two in the third
three-year period. Low voltage of the QRS complex was
found in one patient in the third three-year period.
Echocardiogram
In the sequential evaluation of the four three-year pe-
riods, 26 patients were reevaluated, 12 of whom had sig-
nificant changes: eight had a normal echocardiogram
and suffered alterations and four had an abnormal echo-
cardiogram with a worsening of the condition through-
out the follow up. One patient had an alteration with no
worsening of the condition. Thirteen patients had a nor-
mal echocardiogram and remained without alterations
throughout the study. Evaluation was not possible for 22
patients due to losses occurring in the last 10 years of
follow up; four of these patients had initial alterations
and 18 had no initial alterations.
Pericardial effusion was detected in two patients in the
first three-year period, two in the second three-year
period and two in the fourth three-year period. No
thickening of the pericardium was found. Pulmonary
hypertension was found in one patient in the third
three-year period and one in the fourth three-year
period. LV hypertrophy was found in five patients in the
first three-year period, two patients in the second three-
year period, one patient in the third three-year period
and three in the fourth three-year period. No enlarge-
ment of the left atrium or right ventricle was found,
whereas enlargement of the left ventricle was found in
one patient in the second three-year period.
Segmental LV hypokinesis was found in one patient in
the second three-year period, one in the third three-year
period and one in the fourth three-year period. Diffuse
LV hypokinesis was found in one patient in the fourth
three-year period. Segmental LV akinesis was found in
one patient in the second three-year period and one in
the fourth three-year period. LV diastolic dysfunction
was found in three patients in the second three-year
period and five in the fourth three-year period. LV con-
tractile dysfunction was found in one 1 patient in the
first three-year period, one in the second three-year
period, one in the third three-year period and one in the
fourth three-year period.
Mitral valve thickening was found in two patients in
the second three-year period. Aortic valve thickening oc-
curred in two patients in the second three-year period.
Mitral valve dysfunction was found in nine patients in
the first three-year period, seven in the second three-
year period, four patients in the third three-year period
and seven in the fourth three-year period. Aortic valve
dysfunction was found in two patients in the first three-
year period, two in the second three-year period and one
in the fourth three-year period. Concomitant aortic and
mitral valve dysfunction occurred in one patient in the
first three-year period, two in the second three-year
period, one in the third three-year period and two in the
fourth three-year period. Mitral valve prolapsed occurred
in one patient in the first three-year period and one in
the second three-year period. Mitral annular calcification
occurred in one patient in the second three-year period.
Calcification of the posterior mitral valve leaflet oc-
curred in one patient in the third three-year period and
one in the fourth three-year period. Aortic valve calcifi-
cation was found in one patient in the third three-year
period and one in the fourth three-year period. Tricus-
pid valve dysfunction was found in two patients in the
first three-year period, one in the second three-year
period, one in the third three-year period and one in the
fourth three-year period.
Cardiac stress test
In the sequential evaluation of the four three-year pe-
riods, 10 patients were reevaluated, three of whom had a
normal stress test and suffered significant alterations
throughout the follow up. One patient had an alteration
with no worsening of the condition. Six patients had a
normal stress test and remained without alterations
throughout the study. Evaluation was not possible for 38
patients due to losses occurring in the last 10 years of
follow up; 33 of these patients had no initial alterations
and five did not undergo the stress test on the initial
evaluation. Results suggestive of ischemia were found in
two patients in the second three-year period and one in
the third three-year period. Myocardial effusion imaging
revealed low uptake in the inferior wall in one patient in
the third three-year period.
Coronary angiography, transluminal percutaneous
angioplasty and myocardial revascularization surgery
Coronary angiography was performed five times on four
patients during the years of follow up; four cases re-
quired angioplasty and one was subsequently submitted
to myocardial revascularization surgery. In the first
three-year period, one patient underwent coronary
angiography that demonstrated an 80% obstructive
lesion in the right coronary artery (RCA), for which per-
cutaneous transluminal coronary angioplasty (PTCA)
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was successfully performed. In the second three-year
period, one patient underwent coronary angiography
that demonstrated a 100% obstructive lesion in the RCA
and an 80% obstructive lesion in the circumflex (Cx) ar-
tery, for which PTCA was successfully performed on the
Cx artery, but not attempted on the RCA. In the third
three-year period, two patients underwent coronary
angiography One of these patients demonstrated an 80%
obstructive lesion in the interventricular anterior artery
(IVA), for which PTCA was successfully performed. Fol-
lowing a new angiography, the other case exhibited cor-
onary disease involving the RCA and left anterior
descending artery (LAD), for which myocardial revascu-
larization surgery was performed with the saphenous
vein for the RCA and the left internal thoracic artery for
the LAD. In the fourth three-year period, one patient
underwent coronary angiography that demonstrated a
90% obstructive lesion in the Cx artery and an 80% ob-
structive lesion in the diagonal branch, for which PTCA
was successfully performed on both.
Table 1 summarizes the distribution of the aforemen-
tioned cardiac events based on the analysis of the
complementary exams (chest x-ray, electrocardiogram,
echocardiogram and stress test).
Thirty charts were active and 18 were inactive. Among
the inactive charts, eight were due to the death of the
patient. Two of these deaths were due to heart problems.
The other causes of death were kidney disease and infec-
tious diseases. Figure 1 displays the Kaplan-Meier graph
for the percentage of death-free patients reevaluated
during the 13.6 years of follow up.
Discussion
Considering that patients with SLE are at excess risk of
cardiovascular events and that the excess risk is
suggested to be most pronounced in subjects under 40
years old [14], in the present study, patients with SLE
and a complete cardiologic evaluation in 1998 were
reevaluated through clinical exams for the diagnosis of
changes in the cardiovascular system throughout the
progression of the disease and its possible complications.
The genesis of the pathological mechanism involved in
cardiac comorbidities in autoimmune rheumatology was
enigmatic for many years [15]. Cardiomegaly was found
in 50% of the patients; 11.5% exhibited LV hypertrophy
and 3.8% exhibited LV dilation, which explain the en-
larged heart at the time of the study. In periods of dis-
ease exacerbation, the patients may have developed
myocarditis, which is difficult to detect clinically,
progressing with a slight enlargement of the heart. The
hyperdynamic state described by Andrade Jr. et al. [16]
may also explain the enlarged heart. The increase in
subepicardial adipose tissue in patients with SLE who
have received corticosteroids can lead to a misinterpret-
ation of cardiomegaly on the x-ray, as demonstrated by
Bulkley & Roberts [17].
LV overload was found n 4.1% of the patients in the
third three-year period of the follow up and 8.3% in the
fourth three-year period. The findings are in agreement
with those reported by Doherty et al. [18] in that an
electrocardiogram is not sensitive enough to detect LV
hypertrophy.
Myocardial ischemia was found in 4.1% of the patients
in the first and second three-year periods and 8.3% in
the third three-year period. Necrosis was found in 4.1%
of the patients in the first and second three-year periods
and 8.3% dos patients in the third three-year period.
Badui et al. [7] found ischemia and necrosis in 5% and
11% of patients, respectively. Thus, these findings are
similar to the study cited with regard to ischemia, but
with a smaller prevalence rate regarding necrosis.
Table 1 Distribution of cardiac events based on complementary exams and symptoms
Test Altered with worsening Altered without worsening Unaltered with worsening Unaltered without worsening Total reevaluated
n % n % n % n %
XR 1 3.8 7 26.9 5 19.2 13 50.0 26
ECG 2 8.3 3 12.5 8 33.3 11 45.8 24
ECHO 4 15.4 1 3.8 8 30.8 13 50.0 26
Stress - - 1 10.0 3 30.0 6 60.0 10
XR: X-ray; ECG: Electrocardiogram, ECHO: Echocardiogram.
Figure 1 Survival curve of Kaplan-Meier for free of death at
long term follow-up (until 13.6 years).
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Arrhythmia was characterized by ventricular extrasys-
toles, which were found in 4.1% of the patients in the
first three-year period and 8.3% of patients in the third
three-year period. Arrythmia is generally uncommon
and composed of fibrillation or atrial flutter in patients
with SLE.
The prevalence rate of heart abnormalities detected by
the echocardiogram was 50%, which is similar to the
54% and 57% rates reported by Nihoyannopoulos et al.
[9] and Cervera et al. [10] Pericardial effusion was found
in 7.6% of patients in the first, second and fourth three-
year periods. This prevalence is lower than the rates
described in the international literature by Leung et al.
[19] (17.3%), Nihoyannopoulos et al. [9] (20.,43%) and
Cervera et al. [10] (27%). However, the results of this
study are similar to the prevalence rate reported by
Roldan, Shively, Crawford [20] using transesophageal
echocardiography (7.24%).
No cases of pericardial thickening were found, which
is in agreement with Castier et al. [13] Pericardial alter-
ation is the most frequent heart manifestation in pa-
tients with SLE. Studies report an incidence ranging
from 12% to 100% when studied from the clinical stand-
point [13]. Pericardial effusion was not the most preva-
lent cardiac abnormality in the present study, likely due
to the few patients exhibiting disease activity at the time
of the clinical evaluation.
Pulmonary hypertension was found in as many as 43%
of patients with SLE during the clinical follow up, but is
generally considered an infrequent complication with in-
sidious development and an important cause of death. In
the present study, this complication was found in 3.8% of
patients in the third and fourth three-year periods.
LV hypertrophy was found in 19.2% of patients in the
first three-year period, 7.6% in the second three-year
period, 3.8% in the third three-year period and 11.5% in
the fourth three-year period. Ong et al. [21] found LV
hypertrophy in 20% of patients, which is similar to the
findings of the present study. The prevalence of LV
hypertrophy in patients with SLE may be explained as an
alteration secondary to arterial hypertension associated
with kidney failure and the effects of corticosteroids, as
suggested by Doherty & Siegel [18]. In the present study,
arterial hypertension was found in 62.5% of patients.
Lupus myocarditis is difficult to detect using noninva-
sive methods. However, in an echocardiographic study,
Murai et al. [22] concluded that patients with active SLE
exhibit systolic and diastolic LV dysfunction that is
reversible following treatment with corticosteroids,
suggesting that the heart dysfunction is subjacent to
lupus activity. In the present study, diastolic LV dysfunc-
tion was found in 11.5% of patients in the second three-
year period and 19.2% in the fourth three-year period.
LV contractile dysfunction was found in 3.8% of patients
in each of the four three-year periods. A number of
etiologies have been proposed for lupus cardimyopathy,
such as antibodies directed against cardiac antigens or
the depositing of immune complexes, which may lead to
the activation of the complement system, inflammation
and myocardial damage.
In clinical practice, echocardiography has documented
asymptomatic or subclinical myocardial disease, including
a reduction in the ejection fraction, an increase in the
heart chambers and regional hypokinesis or akinesis
[12,17,22,23]. In the present study, segmental LV
hypokinesis was found in 3.8% of patients in the second,
third and fourth three-year periods. Global LV hypokinesis
was found in 3.8% of the patients in the fourth three-year
period. Segmental LV akinesis was found in 3.8% of the
patients in the second and fourth three-year periods.
Leung et al. [19] report an abnormality rate of 4% regard-
ing the segmental movement of the LV wall.
The spectrum of valvulopathy related to SLE has
expanded and includes valve thickening with signs of
regurgitation or stenosis as well as the more characteris-
tic valve lesion stemming from Libman-Sacks endocar-
ditis (non-bacterial verrucous endocarditis) [11]. In the
present study, endocardium-valve impairment was
mainly characterized by mitral valve lesions. The most
frequent abnormality was mitral regurgitation, which
was found in 34.6% of patients in the first three-year
period, 26.9% in the second three-year period, 15.3% in
the third three-year period and 26.9% in the fourth
three-year period. A number of mechanisms may be in-
volved in the occurrence of mitral failure in patients
with SLE, such as papillary muscle dysfunction, perfor-
ation of the cuspids secondary to vasculitis and fibrotic
adherence of the leaflet posterior to the subjacent endo-
cardium as a consequence of inflammation [11].
The aortic valve was affected in 7.6% of patients in the
first and second three-year periods and 3.8% in the
fourth three-year period, with the detection of leaflet
thickening and regurgitation. Tricuspid valve regurgita-
tion was found in 7.6% of patients in the first three-year
period as well as 3.8% in the second, third and fourth
three-year periods. Metz et al. [24] found aortic regurgi-
tation in 5% of patients, tricuspid regurgitation in 5%
and pulmonary regurgitation in 3%. In the present study,
no pulmonary valve lesions or Libman-Sacks verrucous
lesions were found. The prevalence of SLE-associated
valvulopathy ranges from 18 to 74%, depending on the
group studied, disease duration and method of diagnosis
(autopsy, transthoracic or transesophageal echocardiog-
raphy) [9,12,25,26].
Results of the stress test suggestive of ischemia were
found in three patients throughout the follow up. Low
uptake in the inferior wall was found in only one patient,
in the third three-year period.
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Myocardial infarction was found in four patients
(8.33%) and stroke was found in three patients (4.1%).
The prevalence of myocardial infarction varies in the
literature depending on the method employed. Retro-
spective studies considering only clinical coronary mani-
festations report a prevalence rate of 6%, whereas this
figure ranges from 10 to 54% in prospective studies and
autopsies [27].
While not yet fully clarified, atherogenesis in SLE may
be related to the characteristics of the disease and its
treatment. Atherosclerosis is well defined as a patho-
logical process induced by the use of corticosteroids
[16,28,29]. Complications stemming from this condition,
especially cardiac events, occur more frequently in pa-
tients with SLE for more than five years [27,30,31]. Im-
munoglobulins and components of the complement are
identified on the wall of extramural coronary arteries
with vasculitis. Cytokines, especially interleukin 6, have a
proliferative effect and this action on fibroblasts may con-
tribute to the formation of atherosclerotic plaque. The de-
position of immune complements may lead to arteritis,
luminal narrowing and consequent tissue ischemia [11].
Manzi et al. [32] found that female patients with lupus
between 35 and 44 years of age had a 52-fold greater risk
of cardiovascular events than women in an age-matched
control group. In contrast with the general population,
three out of four patients with lupus with coronary im-
pairment in the present study were under 55 years of
age. Thus, the acceleration of atherosclerosis in patient
with SLE is an undisputable problem, as demonstrated by
the illness and mortality rates stemming from myocardial
infarction, which is its main form of presentation.
While the survival rate among patients with SLE has in-
creased significantly, the mortality rate continues to be
high (approximately threefold greater than that found in
the general population) [33]. In the present study, death
occurred among eight patients. Infection was the main
cause, occurring in four patients (50%), followed by cardio-
vascular disease (2 patients; 25%) and nephropathy (2 pa-
tients; 25%). The deaths by cardiovascular disease were
due to heart failure stemming from lupus myocarditis.
Analyzing 55 patients with a diagnosis of SLE,
Costallat et al. [34] found cardiovascular disorders to be
the second leading cause of death (5 cases with
arrhythmia and 2 cases with congestive heart failure). In
22 autopsies of patients with SLE, Paiva et al. [35] found
that the pericardium was the most often involved
(45.5%), followed by the myocardium (36.4%) and endo-
cardium (22.7%). A proportional increase in death sec-
ondary to cardiovascular alterations has been observed
with the increase in life expectancy of patients with SLE
[36,37]. In this context, Belibu et al. [38] proposed SLE
particularities, since they reported in in North-East
Romania a prevalence of low disease activity and small
impairment disease characteristics may be related to the
effects of early individualized therapy or SLE a specific
profile. On the other hand, the relationship between car-
diovascular disorders and rheumatologic diseases may be
observed often in different situations because rheumato-
logic disorders may affect the heart and vessels [39].
The present study presents some points that are worth
to be raised. It was used descriptive statistical to affirm
the cardiac events of patients of this research had rela-
tion to systemic lupus erythematosus disease. However,
those events could be caused by the aging and athero-
sclerosis or other causes.
Conclusion
The historical prospective analysis of 48 patients with a
confirmed diagnosis of systemic lupus erythematosus
demonstrated progressive heart impairment over a
13-year period, with high rates of abnormalities on con-
ventional complementary exams (chest x-ray, electrocar-
diogram, echocardiogram and stress test), including the
need for angioplasty or revascularization surgery in four
patients. The survival rate at the end of 13 years was
78.8 ± 7.2%, indicating a considerable mortality rate
when considering the young mean age of the sample.
The findings of the present study indicate the need for
rigorous cardiac follow up in patients with systemic
lupus erythematosus.
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